ArticleResearch square2026
Treatment Response in Advanced and Metastatic Esophageal Cancer Patients on Palliative Treatments in Tikur Anbesa Specialized Hospital, Addis Ababa, Ethiopia: A Retrospective Study.
Article in Research square, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Background: Greater than 90 % of oesophageal cancer patients present at an advanced and or metastatic stage in low-income countries including Ethiopia which are also hot spot for this cancer. But there is limited study done on palliative treatment response in Ethiopia. So this study seeks on palliative treatment responses in advanced and metastatic oesophageal cancer patients in the oncology department at TASH. Method: The study is a retrospective cohort of 70 patients with advanced and metastatic oesophageal cancer patients who took palliative treatment at Tikur Anbesa Hospital from June 20, 2019 to November 10, 2022. Data were retrieved from the Hospital-based Cancer Registry to identify patients with esophageal cancers. The overall survival rate was calculated by the Kaplan-Meir method and the correlates between clinical parameters and prognostic significance were estimated by the long-rank test using SPSS version 26.0. We applied a p-value of 0.25 from bivariate to multivariate cox regression analysis and decided a significant at p value of less than 0.05 at multivariate cox-regression analysis. Results: Among the total 70 patients reviewed for this study, 97.6% of them had planned treatment and among those 68.8% took chemotherapy, and 28.6% took surgery. The median overall survival was 17 months. Chemotherapy treatment with chemotherapy has shown overall response rate (ORR) of 21.1%, 18.8% and 3.5% at mid-cycle, end-cycle, and 4 months after completion of chemotherapy respectively. The study also showed that there was at least one-grade improvement of dysphagia in 30% at end-cycle of chemotherapy, and 15% of patients after one month of surgery respectively. The study also highlighted treatment without surgery has a 61.6 % decreased risk of esophageal cancer death (AHR=0.384, 95 CI: 0.161-0.913, P<0.03). Conclusion: Although median overall survival seems higher compared to studies in another part of the world including Africa, Overall response rate and symptomatic dysphagia improvement is very low after completion of chemotherapy and palliative surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.